Dublin, June 24, 2019 (GLOBE NEWSWIRE) -- The "Epilepsy Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Market Snapshot

• Label expansions will drive uptake of newer brands, sustaining the epilepsy market by countering widespread genericization.
• Levetiracetam, valproate formulations, lamotrigine, and carbamazepine constitute the mainstay of epilepsy treatment.
• Although approximately 70% of epilepsy patients respond to treatment, the number of prevalent cases of active epilepsy remains high.
• UCB will continue to dominate the epilepsy market with key drugs Keppra and Vimpat.
• With positive Phase III data in LGS, Epidiolex is proving to be the therapy of choice for refractory childhood epilepsy.

Key Topics Covered

FORECAST: EPILEPSY
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Aptiom/Zebinix (Eslicarbazepine)
Banzel/Inovelon (Rufinamide)
Briviact (Brivaracetam)
Epidiolex (Cannabidiol)
Fycompa (Perampanel)
Keppra/Keppra Xr (Levetiracetam)
Lamictal/Lamictal Xr (Lamotrigine)
Lyrica (Pregabalin)
Onfi (Clobazam)
Vimpat (Lacosamide)
Primary Research Methodology

TREATMENT: EPILEPSY
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Treatment Dynamics
Unmet Needs In Epilepsy

EPIDEMIOLOGY: EPILEPSY
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: EPILEPSY
Overview
Executive Summary
Product Overview
Product Profile: Aptiom
Product Profile: Banzel
Product Profile: Briviact
Product Profile: Fycompa
Product Profile: Keppra And Keppra Xr
Product Profile: Lamictal And Lamictal Xr
Product Profile: Lyrica
Product Profile: Onfi
Product Profile: Vimpat

PIPELINE: EPILEPSY
Overview
Executive Summary
Clinical Pipeline Overview
Latest Analyst Opinion
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Epidiolex
Product Profile (Late Stage): Ganaxolone

For more information about this report visit https://www.researchandmarkets.com/r/2du8us

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.